西罗莫司与标准治疗在卡萨巴赫-梅里特现象中的成本与效果比较：泰国真实世界证据研究

数据集获取（Figshare）

• 源站标题：Cost and effectiveness comparison of sirolimus versus standard treatment in Kasabach-Merritt phenomenon: a real-world evidence study in Thailand
• DOI：10.6084/m9.figshare.25541457.v1
• 发布日期：2024-04-04
• 文件数：3 个
• 文件总体积：83.46 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost_and_effectiveness_comparison_of_sirolimus_versus_standard_treatment_in_Kasabach-Merritt_phenomenon_a_real-world_evidence_study_in_Thailand/25541457

命令行下载

curl -L -o "ipho_a_2300485_sm9547.docx" "https://ndownloader.figshare.com/files/45453126"
curl -L -o "ipho_a_2300485_sm9546.docx" "https://ndownloader.figshare.com/files/45453129"
curl -L -o "ipho_a_2300485_sm9545.docx" "https://ndownloader.figshare.com/files/45453132"

文件清单

• ipho_a_2300485_sm9547.docx（25.50 KB）
• ipho_a_2300485_sm9546.docx（40.88 KB）
• ipho_a_2300485_sm9545.docx（17.07 KB）

文件总体积 83.46 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

The conventional treatment of Kasabach-Merritt Phenomenon (KMP) consists of corticosteroids with vincristine/vinblastine or others. The aim of the study is to compare the first-year direct costs and effectiveness between sirolimus and conventional treatment. A retrospective case-control study of KMP patients was conducted at a mean age of 9 months (1 day to 12 years) between 2000 and 2022 from four tertiary centers in Thailand. The direct costs, hematologic and clinical complete response (HCR, CCR), hospitalization, length of stay, and complications were compared. Of 29 patients, 13 underwent sirolimus (four upfront and nine were refractory to the conventional). The first-year total cost had no statistically significant difference between sirolimus VS conventional treatment (8,852.63 VS 9,083.56 USD: p value: 0.94). The therapeutics achievement was the same in both HCR (244.75 VS 168.94 days; p value: 0.60) and CCR (419.77 VS 399.87 days; p value: 0.90). The subgroup analysis of the first-line sirolimus (n = 4) compared with the conventional (n = 25) showed a more reduced total cost (4,907.84 VS 9,664.05 USD; p value: 0.26) rendered net total cost of −4,756.21 USD per patient (cost saving). A more significant contrast of therapeutic achievement by reduction of both HCR (11.67 VS 224.20 days; p value: 0.36) and CCR (38.50 VS 470.88 days; p value: 0.04) was shown. The sirolimus had no difference in hospitalization, length of stay, and complications. Even though, it was unable to identify significant differences in cost-effectiveness. Sirolimus is suitable for all patients who have diagnosis of KMP either for rescue therapy or first-line treatment.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.25541457.v1（source: https://tandf.figshare.com/articles/dataset/Cost_and_effectiveness_comparison_of_sirolimus_versus_standard_treatment_in_Kasabach-Merritt_phenomenon_a_real-world_evidence_study_in_Thailand/25541457）。